Literature DB >> 1976576

Inhibition of cell mediated cytotoxicity by sulphasalazine: effect of in vivo treatment with 5-aminosalicylic acid and sulphasalazine on in vitro natural killer cell activity.

M N Aparicio-Pagés1, H W Verspaget, J C Hafkenscheid, G E Crama-Bohbouth, A S Peña, I T Weterman, H W Lamers.   

Abstract

Decreased cell mediated cytotoxicity occurs frequently in inflammatory bowel disease, particularly in patients with active disease. It is not clear, however, whether this decrease is caused by the disease or is a consequence of the medical treatment. In this study we evaluated the effect of in vivo treatment with 5-aminosalicylic acid and sulphasalazine on the in vitro natural killer cell activity in five patients with inflammatory bowel disease in remission and in four healthy control subjects in a double blind randomised crossover trial preceded and separated by four weeks of treatment with placebo. The natural killer cell activity was significantly impaired in 67% (six of nine subjects) after four weeks' sulphasalazine treatment and tended to be related to subjects with a slow acetylator phenotype. In contrast, 5-aminosalicylic acid treatment caused only a marginal reaction in the natural killer cell activity in 22% (two of nine subjects). The inhibitory effects were found to be reversible since the decreased natural killer cell activity was completely restored after placebo treatment in all subjects. In conclusion, in vivo treatment with sulphasalazine inhibits the in vitro natural killer cell activity and this seems to be mediated by the sulphapyridine moiety. This phenomenon may contribute to the low natural killer cell activity found in patients with active inflammatory bowel disease.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1976576      PMCID: PMC1378663          DOI: 10.1136/gut.31.9.1030

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  18 in total

1.  Deficient cell-mediated cytotoxicity and hyporesponsiveness to interferon and mitogenic lectin activation by inflammatory bowel disease peripheral blood and intestinal mononuclear cells.

Authors:  R P MacDermott; M J Bragdon; I J Kodner; M J Bertovich
Journal:  Gastroenterology       Date:  1986-01       Impact factor: 22.682

2.  A simple index of Crohn's-disease activity.

Authors:  R F Harvey; J M Bradshaw
Journal:  Lancet       Date:  1980-03-08       Impact factor: 79.321

3.  Immune status in Crohn's disease. V. Decreased in vitro natural killer cell activity in peripheral blood.

Authors:  I O Auer; E Ziemer; H Sommer
Journal:  Clin Exp Immunol       Date:  1980-10       Impact factor: 4.330

4.  Impaired natural killer cell activity in patients with inflammatory bowel disease: evidence for a qualitative defect.

Authors:  C H Ginsburg; J T Dambrauskas; K A Ault; Z M Falchuk
Journal:  Gastroenterology       Date:  1983-10       Impact factor: 22.682

5.  Determination of sulphapyridine and its metabolites in biological materials after administration of salicylazosulphapyridine.

Authors:  K A Hansson; M Sandberg
Journal:  Acta Pharm Suec       Date:  1973-03

6.  Sulphasalazine and derivatives, natural killer activity and ulcerative colitis.

Authors:  P R Gibson; D P Jewell
Journal:  Clin Sci (Lond)       Date:  1985-08       Impact factor: 6.124

7.  Increased suppressor cell activity in inflammatory bowel disease.

Authors:  G Holdstock; B F Chastenay; E L Krawitt
Journal:  Gut       Date:  1981-12       Impact factor: 23.059

8.  Local immune mechanisms in inflammatory bowel disease and colorectal carcinoma. Natural killer cells and their activity.

Authors:  P R Gibson; D P Jewell
Journal:  Gastroenterology       Date:  1986-01       Impact factor: 22.682

9.  Enhanced synthesis of leukotriene B4 by colonic mucosa in inflammatory bowel disease.

Authors:  P Sharon; W F Stenson
Journal:  Gastroenterology       Date:  1984-03       Impact factor: 22.682

10.  Inhibition of cytotoxicity by sulfasalazine. I. Sulfasalazine inhibits spontaneous cell-mediated cytotoxicity by peripheral blood and intestinal mononuclear cells from control and inflammatory bowel disease patients.

Authors:  R P MacDermott; M G Kane; L L Steele; W F Stenson
Journal:  Immunopharmacology       Date:  1986-04
View more
  3 in total

1.  Sulphasalazine inhibits macrophage activation: inhibitory effects on inducible nitric oxide synthase expression, interleukin-12 production and major histocompatibility complex II expression.

Authors:  G Haskó; C Szabó; Z H Németh; E A Deitch
Journal:  Immunology       Date:  2001-08       Impact factor: 7.397

2.  Mucosal 5-aminosalicylic acid concentration inversely correlates with severity of colonic inflammation in patients with ulcerative colitis.

Authors:  G Frieri; R Giacomelli; M Pimpo; G Palumbo; A Passacantando; G Pantaleoni; R Caprilli
Journal:  Gut       Date:  2000-09       Impact factor: 23.059

3.  Mechanism of action of 5-arninosalicylic acid.

Authors:  N A Punchard; S M Greenfield; R P Thompson
Journal:  Mediators Inflamm       Date:  1992       Impact factor: 4.711

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.